Abstract: Disclosed is sublingual administration of riluzole. In particular, a method for treating a neuropsychiatric disorder or symptom by administering a sublingual formulation of riluzole is provided. In addition, a method of relieving or reducing oral pain using the sublingual formulation of riluzole is disclosed.

Abstract: Disclosed is sublingual administration of riluzole. In particular, a method for treating a neuropsychiatric disorder or symptom by administering a sublingual formulation of riluzole is provided. In addition, a method of relieving or reducing oral pain using the sublingual formulation of riluzole is disclosed.

Abstract: Disclosed is sublingual administration of riluzole. In particular, a method for treating a neuropsychiatric disorder or symptom by administering a sublingual formulation of riluzole is provided. In addition, a method of relieving or reducing oral pain using the sublingual formulation of riluzole is disclosed.

Abstract: This disclosure is directed to computing services that provide secure network connections using public-private key-based security for Internet of Things (IoT) devices, such as voice devices, that may have more than a predefined set of users. Device certificates that authorize IoT devices to access a secure network, such as an enterprise network and/or services eternal to an enterprise network are provided. A setup system may cooperate with an IoT device and a subordinate CA to generate a device certificate that allows the IoT device to access a secure enterprise network and services outside of the secure enterprise network. The IoT device may generate a certificate signing request (CSR) which may be signed by a remote subordinate CA to generate the device certificate using a root certificate of an enterprise CA. Systems are also disclosed that renew certificates for the IoT devices prior to their expiration.

Abstract: Disclosed is sublingual administration of riluzole. In particular, a method for treating a neuropsychiatric disorder or symptom by administering a sublingual formulation of riluzole is provided. In addition, a method of relieving or reducing oral pain using the sublingual formulation of riluzole is disclosed.

Abstract: A cover system that may be used for protection of a device such as a smart phone, tablet, or the like. The system includes a body and a cover. The cover may be arranged in a first configuration where the cover is engaged with a first side of the body or a second configuration where the cover is engaged with a second side of the body. The cover may be removable from the body for converting between the first configuration and the second configuration. In the first configuration, the cover may be arranged on a rear of the body and in the second configuration, the cover may be arranged on a front of the body to protect a display of a device retained within the body. As such, additional protection may be selectively provided to the front of a device (e.g., near the display of the device).

Abstract: A cover system that may be used for protection of a device such as a smart phone, tablet, or the like. The system includes a body and a cover. The cover may be arranged in a first configuration where the cover is engaged with a first side of the body or a second configuration where the cover is engaged with a second side of the body. The cover may be removable from the body for converting between the first configuration and the second configuration. In the first configuration, the cover may be arranged on a rear of the body and in the second configuration, the cover may be arranged on a front of the body to protect a display of a device retained within the body. As such, additional protection may be selectively provided to the front of a device (e.g., near the display of the device).

Abstract: Disclosed is sublingual administration of riluzole. In particular, a method for treating a neuropsychiatric disorder or symptom by administering a sublingual formulation of riluzole is provided. In addition, a method of relieving or reducing oral pain using the sublingual formulation of riluzole is disclosed.

Abstract: Methods, systems, and apparatus, including computer programs encoded on a computer storage medium, for cooperatively controlling ambient level lighting in a controlled area, and task-level lighting for task areas in the controlled area, where each task area is a separate sub-area of the controlled area.

Abstract: An oral solid dosage form containing nanoparticles is made by (a) reducing the particle size of at least one pharmaceutically active ingredient dispersed in a solution containing fish gelatin to form a nanosuspension and (b) freeze-drying the nanosuspension of step (a) to form the oral solid dosage form.

Abstract: Methods, systems, and apparatus, including computer programs encoded on a computer storage medium, for cooperatively controlling ambient level lighting in a controlled area, and task-level lighting for task areas in the controlled area, where each task area is a separate sub-area of the controlled area.

Abstract: Methods, systems, and apparatus, including computer programs encoded on a computer storage medium, for cooperatively controlling ambient level lighting in a controlled area, and task level lighting for task areas in the controlled area, wherein each task area is a separate sub-area of the controlled area.

Abstract: Methods, systems, and apparatus, including computer programs encoded on a computer storage medium, for cooperatively controlling ambient level lighting in a controlled area, and task level lighting for task areas in the controlled area, wherein each task area is a separate sub-area of the controlled area.

Abstract: An oral solid dosage form containing nanoparticles is made by (a) reducing the particle size of at least one pharmaceutically active ingredient dispersed in a solution containing fish gelatin to form a nanosuspension and (b) freeze-drying the nanosuspension of step (a) to form the oral solid dosage form.

Abstract: An optical gain flattening filter for attenuating the wavelength power levels of an optical beam to a threshold value. The filter has a series of volume phase gratings which each have a loss spectrum. The sum of the loss spectra for the volume phase gratings is about equal to the opposite of the gain spectrum of the optical amplifier. As the optical beam passes through the volume phase gratings, the sum of the loss spectra is added to the gain spectrum of the optical amplifier such that the optical beam is attenuated to the threshold value.

Abstract: An optical amplifier system for amplifying an input wavelength division multiplexed (WDM) optical signal with a first optical coupler to extract a portion of the power of the input signal, an erbium-doped fiber amplifier to generate an output signal and a second optical coupler to extract a portion of the power of the output signal. A spectral monitoring unit having a volume phase grating separates the extracted input and output signals into spectral components. A photo-detector array of the spectral monitoring unit determines the power level of the spectral components. The system further includes a controller operative to control the operation of the amplifier in response to the power levels of the spectral components.